drugset / Trial / NCT07684937

HL-300 Ointment in Healthy Volunteers

NCT07684937 ↗

Phase 1 Completed 36 enrolled Hangzhou Highlightll Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and tolerability of HL-300 ointment following single and multiple topical administrations in healthy Chinese adult volunteers.

Timeline

Start
2024-06-14
Primary completion
2024-11-25
Completion
2024-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject HL-300 Unknown 0.25 % Topical
Subject HL-300 Unknown 0.5 % Topical
Subject HL-300 Unknown 1 % Topical

Indications